Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
NBIP-'2118 targets a new, non-incretin mechanism for weight loss with lean mass preservation SAN DIEGO, May 4, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the init
At two years, 60% of patients who were overweight or obese at baseline experienced clinically meaningful improvements in body mass index, and 61% of those with insulin resistance at baseline were no l
Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline
11:06am, Thursday, 30'th Apr 2026
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Research published in The Journal of Clinical Psychiatry characterizes patient-reported improvement with INGREZZA® (valbenazine) capsules across the KINECT® clinical program Publication establishes
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Tuesday, 28'th Apr 2026
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Approximately 70% of adult patients treated with CRENESSITY achieved and sustained physiologic‑range glucocorticoid dosing at two years 75% of patients originally taking dexamethasone transitioned o
3 Reasons Growth Investors Will Love Neurocrine (NBIX)
01:46pm, Tuesday, 21'st Apr 2026
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Wall Street Analysts Think Neurocrine (NBIX) Could Surge 38.79%: Read This Before Placing a Bet
10:57am, Tuesday, 21'st Apr 2026
The consensus price target hints at a 38.8% upside potential for Neurocrine (NBIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
Fortis Capital Advisors LLC Invests $1.35 Million in Neurocrine Biosciences, Inc. $NBIX
04:16am, Monday, 20'th Apr 2026
Fortis Capital Advisors LLC bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) during the fourth quarter, according to its most recent disclosure with the Securities and Ex
Is the Options Market Predicting a Spike in Neurocrine Biosciences Stock?
03:36pm, Wednesday, 15'th Apr 2026
Investors need to pay close attention to NBIX stock based on the movements in the options market latel.
Neurocrine Biosciences Inc (NBIX) Stock Up 3.6% and Still Undervalued -- GF Score: 96/100
05:41pm, Tuesday, 14'th Apr 2026
On April 14, 2026, Neurocrine Biosciences Inc (NBIX) shares rose 3.6% to a current price of $130.81. This price is within a 52-week range of $92.31 to $160.18,
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
04:01pm, Tuesday, 14'th Apr 2026
Conference Call and Webcast Scheduled for Tuesday, May 5 SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2
INGREZZA showed higher rates of long-term treatment continuation and lower switching between medications compared to AUSTEDO XR (deutetrabenazine) in a real-world claims analysis among adults with tar
Burney Co. Cuts Stock Holdings in Neurocrine Biosciences, Inc. $NBIX
04:15am, Tuesday, 14'th Apr 2026
Burney Co. reduced its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 69.9% during the undefined quarter, according to the company in its most recent filing with the Securities and
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
07:30pm, Sunday, 12'th Apr 2026
NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine
